Modulation of the contact hypersensitivity response by AE-941 (Neovastat), a novel antiangiogenic agent.
J Cutan Med Surg
; 7(3): 208-16, 2003.
Article
en En
| MEDLINE
| ID: mdl-12574904
ABSTRACT
BACKGROUND:
AE-941 (Neovastat) is an angiogenesis inhibitor noted to have antiinflammatory properties.OBJECTIVE:
We tested Neovastat in a contact hypersensitivity (CHS) model to determine the mechanism of action of its antiinflammatory effects.METHODS:
Neovastat was orally administered (200 mg/kg/day) during the sensitization and challenge phases of a murine CHS assay and inflammatory responses were measured. Subsequent assays were performed on mice treated with Neovastat or Cortisone (120 mg/kg/day, IP) and differential mRNA expression of several pro- and antiinflammatory cytokines was quantified using RT-PCR.RESULTS:
Neovastat decreased inflammation by 39% when administered during sensitization but did not alter the CHS response when given during the challenge phase. Neovastat significantly induced IL-10 expression in skin and skin-draining lymph nodes (49% and 45%, respectively) and decreased IFNgamma expression in the lymph nodes (35%).CONCLUSION:
Antiinflammatory effects of Neovastat observed in CHS could be linked to modulation of cytokines early in the sensitization phase.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Extractos de Tejidos
/
Dermatitis Alérgica por Contacto
/
Inhibidores de la Angiogénesis
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
J Cutan Med Surg
Asunto de la revista:
DERMATOLOGIA
Año:
2003
Tipo del documento:
Article
País de afiliación:
Canadá